Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25:1439-1445
Published online before print April 28, 2005, doi: 10.1161/01.ATV.0000168410.44722.86
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
25/7/1439    most recent
01.ATV.0000168410.44722.86v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Methe, H.
Right arrow Articles by Weis, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Methe, H.
Right arrow Articles by Weis, M.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*ATORVASTATIN
*HEPTANOIC ACID
*PYRROLE
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25:1439.)
© 2005 American Heart Association, Inc.


Atherosclerosis and Lipoproteins

Statins Decrease Toll-Like Receptor 4 Expression and Downstream Signaling in Human CD14+ Monocytes

Heiko Methe; Jong-Oh Kim; Sieglinde Kofler; Michael Nabauer; Michael Weis

From the Department of Cardiology, Ludwig-Maximilians-University, Munich, Germany.

Correspondence to Heiko Methe, MD, Harvard–MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Building 56-322, Cambridge, MA 02139. E-mail hmethe{at}mit.edu

Objective— Anti-inflammatory effects of statins contribute to their clinical benefit. Molecular mechanisms underlying these effects have not been well explored. Because statins attenuate lipopolysaccharide (LPS) responsiveness, we hypothesized that part of the pleiotropic effects are mediated through innate immunity.

Methods and Results— Toll-like receptor (TLR) 4 expression and downstream signaling in CD14+ monocytes after incubation with simvastatin and atorvastatin were quantified via flow-cytometry, quantitative RT-PCR, kinase assay, and enzyme-linked immunosorbent assay. Incubation with intermediates/ inhibitors of the mevalonate pathway was used to identify the mode of statin action. Statin incubation resulted in a dose-dependent reduction of TLR4 expression (53±7.6% reduction compared with untreated monocytes; P<0.005), transcript levels (68±6.3%; P<0.002), decreased IRAK phosphorylation (37±8.3%; P<0.05), and LPS-induced IL-6, IL-12, tumor necrosis factor (TNF)-{alpha}, and B7-1 expression (P<0.05). Four weeks of treatment with atorvastatin significantly reduced TLR4 expression on circulating CD14+ monocytes by 36.2±4.2% (P<0.05). Effects of statins were reversed by mevalonate (P=0.57). Incubation with specific inhibitors of geranylgeranyltransferase (54±4.3%), farnesyltransferase (57±5.1%), or with clostridium-difficile toxin B (58±6.1%, P<0.01) imitated the statin effects. Whereas wortmannin and LY294002 inhibited the statin effect (P=0.27), incubation with a specific RhoA kinase inhibitor had no effect (P=0.57).

Conclusions— Statins influence TLR4 expression and signaling via inhibition of protein geranylgeranylation and farnesylation. These observations imply interactions with innate immunity as one pleiotropic mechanism.

Statin influences on expression and downstream signaling of Toll-like receptor 4 on CD14+ monocytes were assessed. Statins induced a dose-dependent downregulation of TLR4 with subsequent reduction in IRAK activity and cytokine and B7-1 expression. These effects were mediated via inhibition of protein geranylgeranylation and farnesylation. These observations imply a novel mechanism of pleiotropic statin effects.


Key Words: HMG-CoA reductase inhibitors • innate immune system • pleiotropic effects • Toll-like receptor




This article has been cited by other articles:


Home page
J. Leukoc. Biol.Home page
K. P. Sundararaj, D. J. Samuvel, Y. Li, A. Nareika, E. H. Slate, J. J. Sanders, M. F. Lopes-Virella, and Y. Huang
Simvastatin suppresses LPS-induced MMP-1 expression in U937 mononuclear cells by inhibiting protein isoprenylation-mediated ERK activation
J. Leukoc. Biol., October 1, 2008; 84(4): 1120 - 1129.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
A. Moeenrezakhanlou, L. Shephard, L. Lam, and N. E. Reiner
Myeloid cell differentiation in response to calcitriol for expression CD11b and CD14 is regulated by myeloid zinc finger-1 protein downstream of phosphatidylinositol 3-kinase
J. Leukoc. Biol., August 1, 2008; 84(2): 519 - 528.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
H. Shao, Y. Shen, H. Liu, G. Dong, J. Qiang, and H. Jing
Simvastatin Suppresses Lung Inflammatory Response in a Rat Cardiopulmonary Bypass Model
Ann. Thorac. Surg., December 1, 2007; 84(6): 2011 - 2018.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
J. C. Alves-Filho and F. Q. Cunha
Modulation of toll-like receptor expression: a further effect of statins?
Arterioscler. Thromb. Vasc. Biol., July 1, 2006; 26(7): e128 - e128.
[Full Text] [PDF]